Last reviewed · How we verify
biological blood test
A diagnostic blood test that detects and measures biomarkers to identify disease presence or progression.
A diagnostic blood test that detects and measures biomarkers to identify disease presence or progression. Used for Clinical laboratory diagnosis and monitoring (specific indications not detailed).
At a glance
| Generic name | biological blood test |
|---|---|
| Sponsor | Rennes University Hospital |
| Modality | Biologic |
| Therapeutic area | Diagnostics |
| Phase | FDA-approved |
Mechanism of action
Biological blood tests analyze blood samples for specific molecular, cellular, or biochemical markers that indicate disease state, organ function, or treatment response. These tests serve as in vitro diagnostic tools to support clinical decision-making and patient monitoring.
Approved indications
- Clinical laboratory diagnosis and monitoring (specific indications not detailed)
Common side effects
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (PHASE1)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors (PHASE1)
- Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE1)
- Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- biological blood test CI brief — competitive landscape report
- biological blood test updates RSS · CI watch RSS
- Rennes University Hospital portfolio CI